Literature DB >> 19267337

C-peptide in the natural history of type 1 diabetes.

Jerry P Palmer1.   

Abstract

Type 1 diabetes is diagnosed when the patient's endogenous insulin secretion decreases to a level which results in hyperglycemia. After diagnosis, insulin secretion continues to decline. As a reference for clinical trials trying to preserve endogenous beta-cell function in patients with recently diagnosed type 1 diabetes, in this short review I attempt to summarize the natural history of endogenous beta-cell function after the diagnosis of type 1 diabetes.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19267337      PMCID： PMC2895504          DOI： 10.1002/dmrr.943

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN： 1520-7552            Impact factor:   4.876


  29 in total

1.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

2.  Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus.

Authors:  B L Johansson; K Borg; E Fernqvist-Forbes; A Kernell; T Odergren; J Wahren
Journal:  Diabet Med       Date:  2000-03       Impact factor: 4.359

3.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Authors:  Michael W Steffes; Shalamar Sibley; Melissa Jackson; William Thomas
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

4.  Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells.

Authors:  Vincenza Cifarelli; Patrizia Luppi; Hubert M Tse; Jing He; Jon Piganelli; Massimo Trucco
Journal:  Atherosclerosis       Date:  2008-02-21       Impact factor: 5.162

5.  Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes.

Authors:  Karin Ekberg; Tom Brismar; Bo-Lennart Johansson; Björn Jonsson; Per Lindström; John Wahren
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

6.  C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes.

Authors:  Alexander Hansen; Bo-Lennart Johansson; John Wahren; Helene von Bibra
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

7.  Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition.

Authors:  Mary A Cotter; Karin Ekberg; John Wahren; Norman E Cameron
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

8.  C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

Authors:  Jerry P Palmer; G Alexander Fleming; Carla J Greenbaum; Kevan C Herold; Lisa D Jansa; Hubert Kolb; John M Lachin; Kenneth S Polonsky; Paolo Pozzilli; Jay S Skyler; Michael W Steffes
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

9.  C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients.

Authors:  Bo-Lennart Johansson; Jan Sundell; Karin Ekberg; Cathrine Jonsson; Marko Seppänen; Olli Raitakari; Matti Luotolahti; Pirjo Nuutila; John Wahren; Juhani Knuuti
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-09-03       Impact factor: 4.310

10.  C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism.

Authors:  Bo-Lennart Johansson; John Wahren; John Pernow
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-06-10       Impact factor: 4.310
View more
  19 in total

Review 1.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community.

Authors:  Christine L Chan; Iman Taki; Fran Dong; Michelle Hoffman; Jill M Norris; Georgeanna Klingensmith; Marian J Rewers; Andrea K Steck
Journal:  Diabetes Technol Ther       Date:  2015-06-03       Impact factor: 6.118

3.  Alterations of glycaemia, insulin resistance and body mass index within the C-peptide optimal range in non-diabetic patients.

Authors:  Vladimir Kron; Miroslav Verner; Pavel Smetana; Jana Janoutova; Vladimir Janout; Karel Martinik
Journal:  J Appl Biomed       Date:  2020-12-08       Impact factor: 1.797

4.  Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.

Authors:  Emily K Sims; Brian N Bundy; Kenneth Stier; Elisavet Serti; Noha Lim; S Alice Long; Susan M Geyer; Antoinette Moran; Carla J Greenbaum; Carmella Evans-Molina; Kevan C Herold
Journal:  Sci Transl Med       Date:  2021-03-03       Impact factor: 17.956

5.  Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.

Authors:  Carla J Greenbaum; Craig A Beam; David Boulware; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; John M Lachin; Paula McGee; Jerry P Palmer; Mark D Pescovitz; Heidi Krause-Steinrauf; Jay S Skyler; Jay M Sosenko
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.337

6.  Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls.

Authors:  Andrea K Steck; Helena Elding Larsson; Xiang Liu; Riitta Veijola; Jorma Toppari; William A Hagopian; Michael J Haller; Simi Ahmed; Beena Akolkar; Åke Lernmark; Marian J Rewers; Jeffrey P Krischer
Journal:  Pediatr Diabetes       Date:  2017-01-27       Impact factor: 3.409

7.  No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial.

Authors:  Carla Bizzarri; Dario Pitocco; Nicola Napoli; Enrico Di Stasio; Daria Maggi; Silvia Manfrini; Concetta Suraci; Maria Gisella Cavallo; Marco Cappa; Giovanni Ghirlanda; Paolo Pozzilli
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

8.  Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database.

Authors:  David M Tridgell; Charles Spiekerman; Richard S Wang; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2011-02-17       Impact factor: 19.112

9.  Rapid Point-of-Care Test for Determination of C-Peptide Levels.

Authors:  Paturi V Rao; Eric Bean; Dhanalakshmi Nair-Schaef; Siting Chen; Steven C Kazmierczak; Charles T Roberts; Srinivasa R Nagalla
Journal:  J Diabetes Sci Technol       Date:  2021-03-17

10.  Factors Associated With the Decline of C-Peptide in a Cohort of Young Children Diagnosed With Type 1 Diabetes.

Authors:  Andrea K Steck; Xiang Liu; Jeffrey P Krischer; Michael J Haller; Riitta Veijola; Markus Lundgren; Simi Ahmed; Beena Akolkar; Jorma Toppari; William A Hagopian; Marian J Rewers; Helena Elding Larsson
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 6.134
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.